ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Roivant Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Market Cap | $25.06B | $197.05M |
| Enterprise Value | $21.91B | $106.56M |
| PS Ratio | 3327.75 | 3.93 |
| PB Ratio | 5.92 | 2.14 |
| P/TBV Ratio | 5.92 | 2.46 |
Enterprise value
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| EV / Sales | 2909.34 | 2.69 |
Income (trailing twelve months)
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Revenue | $7.53M | $57.94M |
| Operating Income | -$596.14M | -$21.44M |
| Pretax Income | -$289.88M | -$14.45M |
| Net Income | -$266.25M | -$22.46M |
| EBITDA | -$593.29M | -$16.91M |
| EPS (Diluted) | -$0.39 | -$0.83 |
Margins
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Operating Margin | -7914.7% | -44.5% |
| Pretax Margin | -3848.7% | -13.0% |
| Profit Margin | -3535.0% | -39.2% |
| EBITDA Margin | -7876.9% | -31.3% |
| FCF Margin | -10901.0% | -8.85% |
Returns
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -6.21% | -53.1% |
| Return on Assets (ROA) | -5.15% | -41.0% |
| Return on Invested Capital (ROIC) | -406.6% | -32.0% |
| Return on Capital Employed (ROCE) | -11.9% | -37.8% |
Growth
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -67.6% | 6.01% |
| Revenue Growth (3Y CAGR) | -36.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -19.1% | 6.42% |
Balance sheet
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.84B | $62.42M |
| Net Cash (Debt) | $3.84B | $15.68M |
| Net Cash Per Share | $5.32 | $0.65 |
| Equity (Book Value) | $4.23B | $48.79M |
| Book Value Per Share | $5.86 | $1.36 |
| Tangible Book Value | $4.23B | $23.06M |
| Working Capital | $4.46B | $75.77M |
Financial position
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Current Ratio | 16.72 | 3.30 |
| Quick Ratio | 13.55 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$816.47M | -$12.35M |
| Capital Expenditures | -$4.59M | -$1.06M |
| Free Cash Flow | -$821.06M | -$20.28M |
| FCF Per Share | -$1.14 | -$0.41 |
Efficiency
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $10.45K | $398.96K |
| Profits Per Employee | -$369.28K | -$732.08K |
| Employee Count | 721 | 73 |
Dividends and yields
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Earnings Yield | -1.06% | -21.2% |
| FCF Yield | -3.28% | -7.64% |
Shares
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 722,323,000 | 59,128,900 |
| Shares Change (YoY) | -1.06% | 11.1% |
| Shares Change (QoQ) | 0.32% | 0.54% |
| Float | 619,321,000 | 48,744,500 |
| Shares Held by Insiders | 14.3% | 11.8% |
| Shares Held by Institutions | 78.1% | 59.4% |
Taxes
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Income Tax | $124.72M | $91.50K |
Scores
| Measure | Roivant Sciences | Industry median |
|---|---|---|
| Altman Z-Score | 39.50 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Roivant Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.